< h1> Revolutionizing Cancer Care: GenomOncology and City of Hope Forge a Powerful Alliance to Advance Precision Oncology
In the relentless pursuit of improving patient outcomes and revolutionizing cancer care, GenomOncology and City of Hope, two entities at the forefront of precision oncology, have joined forces to embark on a groundbreaking collaboration. This partnership aims to enhance City of Hope’s natural language processing (NLP) pipeline through the integration of HopeIQ, a data enablement solution powered by GenomOncology’s igniteIQ platform. This strategic alliance marks a significant milestone in the advancement of precision medicine, bringing together expertise and innovative technologies to transform cancer treatment and research.
City of Hope: A Pioneer in Precision Medicine
City of Hope stands tall as one of the nation’s leading cancer research and treatment organizations, renowned for its unwavering commitment to precision medicine. Through the establishment of POSEIDON (Precision Oncology Software Environment Interoperable Data Ontologies Network), an award-winning, enterprise-wide data lake platform, City of Hope has taken great strides in providing patient-specific insights and recommendations grounded in real-world data and evidence.
GenomOncology: Empowering Precision Medicine with Data-Driven Insights
GenomOncology, a trailblazing software company dedicated to improving cancer care through data-driven insights, brings a wealth of expertise and innovative solutions to this partnership. Their flagship Precision Oncology Platform (POP) serves as the foundation for a comprehensive suite of end-to-end software solutions that empower healthcare providers with actionable oncology treatment options and strategic insights.
HopeIQ: Unlocking the Power of Real-World Data
HopeIQ, the cornerstone of this collaboration, is GenomOncology’s augmented NLP data curation solution that seamlessly integrates with City of Hope’s POSEIDON platform. This state-of-the-art technology harnesses the power of the expert-in-loop model, biomarker normalization, and structure detection to streamline natural language processing and ensure accuracy in data analysis.
Enhancing Data Integration and Utilization
The integration of HopeIQ into POSEIDON has yielded remarkable results, enabling the structuring of over 14,000 patient reports and unstructured disease-based evidence, including breast carcinoma and leukemia pathology reports, as well as clinicians’ notes, with an impressive accuracy rate exceeding 95%. This seamless data integration and utilization optimizes research and treatment opportunities, ultimately improving patient outcomes.
GenomOncology’s igniteIQ: A Game-Changer in Data Enablement
GenomOncology’s igniteIQ, the driving force behind HopeIQ, stands as a testament to the company’s unwavering commitment to precision medicine. This focused and automated data enablement solution simplifies the extraction of medical information from diverse documents and images, adhering to stringent legal standards to safeguard patient privacy and security.
Quotes from Key Figures
Ian Maurer, Chief Technology Officer at GenomOncology, expressed his enthusiasm for the collaboration, highlighting the transformative impact of HopeIQ and GenomOncology’s data curation services in advancing data extraction, curation, and structuring. This, he emphasized, simplifies the integration of real-world data into the POSEIDON platform, thereby enhancing patient treatment research and unlocking new opportunities.
Samir Courdy, Senior VP of Informatics at City of Hope, echoed this sentiment, emphasizing the institution’s dedication to leading the charge in precision oncology research and treatment. He lauded the infrastructure being built, which translates vast clinico-genomic data into actionable information for research and clinical decision-making. City of Hope’s unwavering commitment to providing genomic information to cancer patients and their genetically at-risk family members serves as a testament to their unwavering dedication to improving patient outcomes.
GenomOncology: A Trailblazer in Precision Oncology
GenomOncology’s unwavering commitment to improving cancer care through data-driven insights has positioned the company as a trailblazer in the field of precision oncology. Their comprehensive suite of software solutions, powered by the Precision Oncology Platform (POP), empowers healthcare providers with the information they need to make informed decisions, ultimately enhancing patient outcomes.
Media Contact
For further information or media inquiries, Alysia Kaplan, Director of Marketing at GenomOncology, can be reached at (440) 617-6087 or via email at [email protected].
Additional Resources
To delve deeper into GenomOncology’s groundbreaking work in precision oncology and explore the transformative potential of their data-driven solutions, visit their website at www.genomoncology.com.